ROCK and JAK1 signaling cooperate to control actomyosin contractility in tumor cells and stroma.

[1]  Peter Olson,et al.  Cancer-Associated Fibroblasts Are Activated in Incipient Neoplasia to Orchestrate Tumor-Promoting Inflammation in an NF-kappaB-Dependent Manner. , 2010, Cancer cell.

[2]  R. Torres,et al.  The Rho exchange factor Arhgef1 mediates the effects of angiotensin II on vascular tone and blood pressure , 2010, Nature Medicine.

[3]  M. Karin,et al.  Inflammation and oncogenesis: a vicious connection. , 2010, Current opinion in genetics & development.

[4]  P. Friedl,et al.  The Journal of Cell Biology , 2002 .

[5]  E. Sahai,et al.  A chemical biology screen reveals a role for Rab21-mediated control of actomyosin contractility in fibroblast-driven cancer invasion , 2009, British Journal of Cancer.

[6]  James E. Thompson and.  Photochemical Preparation of a Pyridone Containing Tetracycle: A Jak Protein Kinase Inhibitor. , 2010 .

[7]  Larry Norton,et al.  Tumor Self-Seeding by Circulating Cancer Cells , 2009, Cell.

[8]  Hua Yu,et al.  STATs in cancer inflammation and immunity: a leading role for STAT3 , 2009, Nature Reviews Cancer.

[9]  H. Drexler,et al.  Hepatocyte gp130 Deficiency Reduces Vascular Remodeling After Carotid Artery Ligation , 2009, Hypertension.

[10]  E. Sahai,et al.  Intravital imaging reveals transient changes in pigment production and Brn2 expression during metastatic melanoma dissemination. , 2009, Cancer research.

[11]  M. Bar‐eli,et al.  Inflammation and melanoma metastasis , 2009, Pigment cell & melanoma research.

[12]  Timothy C Wang,et al.  Inflammation and cancer: IL-6 and STAT3 complete the link. , 2009, Cancer cell.

[13]  M. Karin,et al.  IL-6 and Stat3 are required for survival of intestinal epithelial cells and development of colitis-associated cancer. , 2009, Cancer cell.

[14]  Ozge Canli,et al.  gp130-mediated Stat3 activation in enterocytes regulates cell survival and cell-cycle progression during colitis-associated tumorigenesis. , 2009, Cancer cell.

[15]  B. Aggarwal,et al.  Targeting Inflammatory Pathways for Prevention and Therapy of Cancer: Short-Term Friend, Long-Term Foe , 2009, Clinical Cancer Research.

[16]  P. Yue,et al.  Targeting STAT3 in cancer: how successful are we? , 2009, Expert opinion on investigational drugs.

[17]  M. Feldman,et al.  Activated STAT3 is a mediator and biomarker of VEGF endothelial activation , 2008, Cancer biology & therapy.

[18]  N. Todd,et al.  Mechanisms of Oncostatin M-Induced Pulmonary Inflammation and Fibrosis , 2008, The Journal of Immunology.

[19]  E. Sahai,et al.  Rac Activation and Inactivation Control Plasticity of Tumor Cell Movement , 2008, Cell.

[20]  E. Sahai,et al.  Imaging amoeboid cancer cell motility in vivo , 2008, Journal of microscopy.

[21]  Jane Fridlyand,et al.  Improving Melanoma Classification by Integrating Genetic and Morphologic Features , 2008, PLoS medicine.

[22]  K. Venkatasubbarao,et al.  Inhibition of STAT3 Tyr705 phosphorylation by Smad4 suppresses transforming growth factor beta-mediated invasion and metastasis in pancreatic cancer cells. , 2008, Cancer research.

[23]  Ying-Xuan Chen,et al.  Inhibition of JAK1, 2/STAT3 signaling induces apoptosis, cell cycle arrest, and reduces tumor cell invasion in colorectal cancer cells. , 2008, Neoplasia.

[24]  Xin-Yun Huang,et al.  Identification of Novel Direct Stat3 Target Genes for Control of Growth and Differentiation* , 2008, Journal of Biological Chemistry.

[25]  H. Zhang,et al.  Fra-1 and Stat3 synergistically regulate activation of human MMP-9 gene. , 2008, Molecular immunology.

[26]  E. Sahai,et al.  Fibroblast-led collective invasion of carcinoma cells with differing roles for RhoGTPases in leading and following cells , 2007, Nature Cell Biology.

[27]  N. Coleman,et al.  Gain and overexpression of the oncostatin M receptor occur frequently in cervical squamous cell carcinoma and are associated with adverse clinical outcome , 2007, The Journal of pathology.

[28]  D. Radisky,et al.  Fibrosis and cancer: Do myofibroblasts come also from epithelial cells via EMT? , 2007, Journal of cellular biochemistry.

[29]  J. Scheller,et al.  The IL-6/sIL-6R complex as a novel target for therapeutic approaches , 2007, Expert opinion on therapeutic targets.

[30]  T. Nakayama,et al.  Expression of p-STAT3 in human gastric carcinoma: significant correlation in tumour invasion and prognosis. , 2007, International journal of oncology.

[31]  Paolo P. Provenzano,et al.  Collagen reorganization at the tumor-stromal interface facilitates local invasion , 2006, BMC medicine.

[32]  J. Bromberg,et al.  Pyridone 6, a pan-Janus-activated kinase inhibitor, induces growth inhibition of multiple myeloma cells. , 2006, Cancer research.

[33]  John S. Condeelis,et al.  ROCK- and Myosin-Dependent Matrix Deformation Enables Protease-Independent Tumor-Cell Invasion In Vivo , 2006, Current Biology.

[34]  Raghu Kalluri,et al.  Fibroblasts in cancer , 2006, Nature Reviews Cancer.

[35]  M. Olson,et al.  Conditional regulation of a ROCK-estrogen receptor fusion protein. , 2006, Methods in enzymology.

[36]  C. Marshall,et al.  Cdc42–MRCK and Rho–ROCK signalling cooperate in myosin phosphorylation and cell invasion , 2005, Nature Cell Biology.

[37]  Michael P. Sheetz,et al.  Basic mechanism of three-dimensional collagen fibre transport by fibroblasts , 2005, Nature Cell Biology.

[38]  伊藤 美幸.  Requirement of STAT3 activation for maximal collagenase-1 (MMP-1) induction by epidermal growth factor and malignant characteristics in T24 bladder cancer cells , 2005 .

[39]  Gordon K. Smyth,et al.  limma: Linear Models for Microarray Data , 2005 .

[40]  O. Silvennoinen,et al.  The Janus kinases (Jaks) , 2004, Genome Biology.

[41]  Jean YH Yang,et al.  Bioconductor: open software development for computational biology and bioinformatics , 2004, Genome Biology.

[42]  J. Bromberg,et al.  Stat3 is required for the development of skin cancer. , 2004, The Journal of clinical investigation.

[43]  Michael Karin,et al.  IKKβ Links Inflammation and Tumorigenesis in a Mouse Model of Colitis-Associated Cancer , 2004, Cell.

[44]  F. Ali-Osman,et al.  Stat3 activation regulates the expression of matrix metalloproteinase-2 and tumor invasion and metastasis , 2004, Oncogene.

[45]  D. Hartshorne,et al.  Myosin phosphatase: Structure, regulation and function , 2004, Molecular and Cellular Biochemistry.

[46]  Benjamin M. Bolstad,et al.  affy - analysis of Affymetrix GeneChip data at the probe level , 2004, Bioinform..

[47]  R. Mason,et al.  Oncostatin M, a cytokine released by activated mononuclear cells, induces epithelial cell-myofibroblast transdifferentiation via Jak/Stat pathway activation. , 2004, Journal of the American Society of Nephrology : JASN.

[48]  L. Coussens,et al.  The tumor microenvironment: a critical determinant of neoplastic evolution. , 2003, European journal of cell biology.

[49]  P. Friedl,et al.  Proteolytic and non-proteolytic migration of tumour cells and leucocytes. , 2003, Biochemical Society symposium.

[50]  Erik Sahai,et al.  Differing modes of tumour cell invasion have distinct requirements for Rho/ROCK signalling and extracellular proteolysis , 2003, Nature Cell Biology.

[51]  Olivier De Wever,et al.  Role of tissue stroma in cancer cell invasion , 2003, The Journal of pathology.

[52]  Frederick Grinnell,et al.  Fibroblast biology in three-dimensional collagen matrices. , 2003, Trends in cell biology.

[53]  P. Friedl,et al.  Tumour-cell invasion and migration: diversity and escape mechanisms , 2003, Nature Reviews Cancer.

[54]  Timothy J Mitchison,et al.  Dissecting Temporal and Spatial Control of Cytokinesis with a Myosin II Inhibitor , 2003, Science.

[55]  Peter Friedl,et al.  Compensation mechanism in tumor cell migration , 2003, The Journal of cell biology.

[56]  Massimo Gadina,et al.  Cytokine Signaling in 2002 New Surprises in the Jak/Stat Pathway , 2002, Cell.

[57]  R. Perona,et al.  Simultaneous tyrosine and serine phosphorylation of STAT3 transcription factor is involved in Rho A GTPase oncogenic transformation. , 2001, Molecular biology of the cell.

[58]  H. L. Vos,et al.  A STAT-responsive Element in the Promoter of the Episialin/MUC1 Gene Is Involved in Its Overexpression in Carcinoma Cells* , 2001, The Journal of Biological Chemistry.

[59]  J. Darnell,et al.  Stat3 as an Oncogene , 1999, Cell.

[60]  M. Herlyn,et al.  Immunohistochemical evidence of cytokine networks during progression of human melanocytic lesions , 1999, International journal of cancer.

[61]  J. Turkson,et al.  Constitutive activation of Stat3 signaling confers resistance to apoptosis in human U266 myeloma cells. , 1999, Immunity.

[62]  M. Goldsmith,et al.  Janus kinases in interleukin-2-mediated signaling: JAK1 and JAK3 are differentially regulated by tyrosine phosphorylation , 1997, Current Biology.

[63]  C. O’Brien,et al.  Isolation and Characterization of the Human gp130 Promoter , 1997, The Journal of Biological Chemistry.

[64]  Comeau,et al.  The IL-6 signal transducer, gp130: an oncostatin M receptor and affinity converter for the LIF receptor. , 1992, Science.

[65]  I. M. Neiman,et al.  [Inflammation and cancer]. , 1974, Patologicheskaia fiziologiia i eksperimental'naia terapiia.